Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma
- Authors:
- Libin Xu
- Xianbiao Xie
- Xiaoliang Shi
- Peng Zhang
- Angen Liu
- Jian Wang
- Bo Zhang
-
Affiliations: Department of Orthopedic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China, Department of Musculoskeletal Oncology, The First Affiliated Hospital of Sun Yat Sen University, Guangzhou, Guangdong 510080, P.R. China, OrigiMed Co. Ltd., Shanghai 201114, P.R. China, Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China, Department of Pathology, Peking University Third Hospital, Beijing 100191, P.R. China - Published online on: March 4, 2021 https://doi.org/10.3892/ol.2021.12614
- Article Number: 353
-
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
|
Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S and Ladanyi M: Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer. 11:541–557. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, Samonigg H, Glehr M, Zacherl M, Stojakovic T, Gerger A and Leithner A: Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer. 108:1677–1683. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chan JY, Zhang Z, Chew W, Tan GF, Lim CL, Zhou L, Goh WL, Poon E, Somasundaram N, Selvarajan S, et al: Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Sci Rep. 8:119592018. View Article : Google Scholar : PubMed/NCBI | |
|
Somasundaram N, Chan SH, Quek R and Ngeow J: Chapter 43-Advances in Sarcoma Genomics and Therapeutic Management. In: Oncogenomics. Dammacco F and Silvestris F: Academic Press; pp. 609–621. 2019 | |
|
Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou B, Lansiaux A, et al: Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: An ancillary study from a phase II trial. Target Oncol. 9:273–277. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Serranogarcia C, Heinrich MC, Zhu M, Raut CP, Eilers G, Ravegnini G, Demetri GD, Bauer S, Fletcher JA and George S: In vitro and in vivo activity of regorafenib (REGO) in drug-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 31 (Suppl 15):10510. 2013. View Article : Google Scholar | |
|
Rickel K, Fang F and Tao J: Molecular genetics of osteosarcoma. Bone. 102:69–79. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Maguire M: Comment on: Early symptoms of bone and soft tissue sarcomas: Could they be diagnosed earlier? Ann R Coll Surg Engl. 94:4512012. View Article : Google Scholar : PubMed/NCBI | |
|
Scurr M and Judson I: Sarcoma. Cancer Chemother Biol Response Modif. 21:637–653. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hastings CA, Torkildson JC and Agrawal AK: Sarcomas of the Soft Tissues and Bone. Handbook of Pediatric Hematology and Oncology: Children's Hospital & Research Center Oakland: Second edition. pp. 183–192. 2012, View Article : Google Scholar | |
|
Sinha S and Peach AH: Diagnosis and management of soft tissue sarcoma. BMJ. 341:c71702010. View Article : Google Scholar : PubMed/NCBI | |
|
Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S and Strauss SJ: Incidence and survival of malignant bone sarcomas in England 1979–2007. Int J Cancer. 131:E508–E517. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Chen Y, Cui T, Knösel T, Zhang Q, Geier C, Katenkamp D and Petersen I: Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma. Hum Pathol. 43:1463–1470. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
van Brummelen EMJ, de Boer A, Beijnen JH and Schellens JHM: BRAF mutations as predictive biomarker for response to Anti-EGFR monoclonal antibodies. Oncologist. 22:864–872. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Evola FR, Costarella L, Pavone V, Caff G, Cannavò L, Sessa A, Avondo S and Sessa G: Biomarkers of osteosarcoma, chondrosarcoma, and ewing sarcoma. Front Pharmacol. 8:1502017. View Article : Google Scholar : PubMed/NCBI | |
|
Hutanu D, Popescu R, Stefanescu H, Pirtea L, Candea A, Sarau C, Boruga O, Mehdi L, Ciuca I and Tanasescu S: The molecular genetic expression as a novel biomarker in the evaluation and monitoring of patients with osteosarcoma-subtype bone cancer disease. Biochem Genet. 55:291–299. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome atlas Pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Electronic address simpleelizabeth.demicco@sinaihealthsystem.ca. et al Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 171:950–965.e28. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, Wong SH, Rabe S, Hlevnjak M, Zapatka M, et al: Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 9:1442018. View Article : Google Scholar : PubMed/NCBI | |
|
Mertens F, Antonescu CR and Mitelman F: Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes. Genes Chromosomes Cancer. 55:291–310. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Italiano A, Bianchini L, Gjernes E, Keslair F, Ranchere-Vince D, Dumollard JM, Haudebourg J, Leroux A, Mainguené C, Terrier P, et al: Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Clin Cancer Res. 15:5696–5703. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chibon F, Lagarde P, Salas S, Pérot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, et al: Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 16:781–787. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sankar S and Lessnick SL: Promiscuous partnerships in Ewing's sarcoma. Cancer Genet. 204:351–365. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Fligman I, Lonardo F, Jhanwar SC, Gerald WL, Woodruff J and Ladanyi M: Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol. 147:1592–1599. 1995.PubMed/NCBI | |
|
Antonescu CR, Tschernyavsky SJ, Woodruff JM, Jungbluth AA, Brennan MF and Ladanyi M: Molecular diagnosis of clear cell sarcoma: Detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J Mol Diagn. 4:44–52. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kubota T: Gastrointestinal stromal tumor (GIST) and imatinib. Int J Clin Oncol. 11:184–189. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Stacchiotti S, Crippa F, Messina A, Pilotti S, Gronchi A, Blay JY and Casali PG: Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin Sarcoma Res. 3:82013. View Article : Google Scholar : PubMed/NCBI | |
|
Rausch JL, Boichuk S, Ali AA, Patil SS, Liu L, Lee DM, Brown MF, Makielski KR, Liu Y, Taguchi T, et al: Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Oncotarget. 8:4471–4483. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Dickson MA, Tap WD, Keohan ML, D'Angelo SP, Gounder MM, Antonescu CR, Landa J, Qin LX, Rathbone DD, Condy MM, et al: Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 31:2024–2028. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Knezevich SR, McFadden DE, Tao W, Lim JF and Sorensen PH: A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 18:184–187. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Haller F, Knopf J, Ackermann A, Bieg M, Kleinheinz K, Schlesner M, Moskalev EA, Will R, Satir AA, Abdelmagid IE, et al: Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: A subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol. 238:700–710. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gibault L, Pérot G, Chibon F, Bonnin S, Lagarde P, Terrier P, Coindre JM and Aurias A: New insights in sarcoma oncogenesis: A comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol. 223:64–71. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schaefer IM, Cote GM and Hornick JL: Contemporary sarcoma diagnosis, genetics, and genomics. J Clin Oncol. 36:101–110. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Krystel-Whittemore M, Taylor MS, Rivera M, Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Deshpande V, Chebib I, Nielsen GP, et al: Novel and established EWSR1 gene fusions and associations identified by next generation sequencing and fluorescence in-situ hybridization. Hum Pathol. 93:65–73. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liang X, Li Q, Xu B, Hu S, Wang Q, Li Y, Zong Y, Zhang S and Li C: Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas. Int J Clin Oncol. 24:1061–1068. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng B, Qu Y, Wang J, Shi Y and Yan W: Pathogenic and targetable genetic alterations in resected recurrent undifferentiated pleomorphic sarcomas identified by targeted next-generation sequencing. Cancer Genomics Proteomics. 16:221–228. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Nagy A, Bhaduri A, Shahmarvand N, Shahryari J, Zehnder JL, Warnke RA, Mughal T, Ali S and Ohgami RS: Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. Blood Adv. 2:481–491. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, Kurachi H, Sasaki M, Wakasa K, Inoue M, et al: Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer. 80:458–467. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, et al: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 52:6194–6199. 1992.PubMed/NCBI | |
|
Quinlan DC, Davidson AG, Summers CL, Warden HE and Doshi HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52:4828–4831. 1992.PubMed/NCBI | |
|
Li JP, Zhang XM, Zhang Z, Zheng LH, Jindal S and Liu YJ: Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine (Baltimore). 98:e154492019. View Article : Google Scholar : PubMed/NCBI | |
|
Cho SY, Park C, Na D, Han JY, Lee J, Park OK, Zhang C, Sung CO, Moon HE, Kim Y, et al: High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Exp Mol Med. 49:e3172017. View Article : Google Scholar : PubMed/NCBI | |
|
Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T and Kaneko Y: Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 120:91–98. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH, Gorlick R, Meyers P and Ladanyi M: Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: A highly lethal subset associated with poor chemoresponse. J Clin Oncol. 23:548–558. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Oshiro Y, Chaturvedi V, Hayden D, Nazeer T, Johnson M, Johnston DA, Ordóñez NG, Ayala AG and Czerniak B: Altered p53 is associated with aggressive behavior of chondrosarcoma: A long term follow-up study. Cancer. 83:2324–2334. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Antonescu CR, Tschernyavsky SJ, Decuseara R, Leung DH, Woodruff JM, Brennan MF, Bridge JA, Neff JR, Goldblum JR and Ladanyi M: Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: A molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 7:3977–3987. 2001.PubMed/NCBI | |
|
Italiano A, Di Mauro I, Rapp J, Pierron G, Auger N, Alberti L, Chibon F, Escande F, Voegeli AC, Ghnassia JP, et al: Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): A prospective, multicentre, observational study. Lancet Oncol. 17:532–538. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Llombart B, Monteagudo C, Sanmartin O, López-Guerrero JA, Serra-Guillén C, Poveda A, Jorda E, Fernandez-Serra A, Pellín A, Guillén C and Llombart-Bosch A: Dermatofibrosarcoma protuberans: A clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol. 65:564–575. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kammerer-Jacquet SF, Thierry S, Cabillic F, Lannes M, Burtin F, Henno S, Dugay F, Bouzillé G, Rioux-Leclercq N, Belaud-Rotureau MA and Stock N: Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: Utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. Hum Pathol. 59:34–40. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SK and Park YK: Ewing sarcoma: A chronicle of molecular pathogenesis. Hum Pathol. 55:91–100. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
El Beaino M, Araujo DM, Lazar AJ and Lin PP: Synovial sarcoma: Advances in diagnosis and treatment identification of new biologic targets to improve multimodal therapy. Ann Surg Oncol. 24:2145–2154. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pierron G, Tirode F, Lucchesi C, Reynaud S, Ballet S, Cohen-Gogo S, Perrin V, Coindre JM and Delattre O: A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion. Nat Genet. 44:461–466. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida A, Goto K, Kodaira M, Kobayashi E, Kawamoto H, Mori T, Yoshimoto S, Endo O, Kodama N, Kushima R, et al: CIC-rearranged Sarcomas: A study of 20 cases and comparisons with Ewing sarcomas. Am J Surg Pathol. 40:313–323. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Michal M, Berry RS, Rubin BP, Kilpatrick SE, Agaimy A, Kazakov DV, Steiner P, Ptakova N, Martinek P, Hadravsky L, et al: EWSR1-SMAD3-rearranged Fibroblastic Tumor: An Emerging Entity in an Increasingly More Complex Group of Fibroblastic/Myofibroblastic Neoplasms. Am J Surg Pathol. 42:1325–1333. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, et al: NTRK fusions define a novel uterine sarcoma subtype with features of fibrosarcoma. Am J Surg Pathol. 42:791–798. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Fletcher JA and Rubin BP: KIT mutations in GIST. Curr Opin Genet Dev. 17:3–7. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ren W and Gu G: Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: A meta-analysis. Eur J Cancer Care (Engl). 262017.doi: 10.1111/ecc.12401. | |
|
Müller L, Hainberger D, Stolz V, Hamminger P, Hassan H, Preglej T, Boucheron N, Sakaguchi S, Wiegers GJ, Villunger A, et al: The corepressor NCOR1 regulates the survival of single-positive thymocytes. Sci Rep. 7:159282017. View Article : Google Scholar : PubMed/NCBI | |
|
Noblejas-Lopez MDM, Morcillo-Garcia S, Nieto-Jimenez C, Nuncia-Cantarero M, Győrffy B, Galan-Moya EM, Pandiella A and Ocaña A: Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene. PLoS One. 13:e02077762018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Song XW, Bu XM, Zhang N and Zhao CH: PDCD2 and NCoR1 as putative tumor suppressors in gastric gastrointestinal stromal tumors. Cell Oncol (Dordr). 39:129–137. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, et al: Genomic landscape of liposarcoma. Oncotarget. 6:42429–42444. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I and Coindre JM: MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: A comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 29:1340–1347. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Z, Chen H, Chen M, He X, Wang Y and Zhang H: Application of COL1A1-PDGFB fusion gene detection by fluorescence in situ hybridization in biopsy tissue of dermatofibrosarcoma protuberans. J Dermatol. 44:798–802. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bianchi G, Sambri A, Pedrini E, Pazzaglia L, Sangiorgi L, Ruengwanichayakun P, Donati D, Benassi MS and Righi A: Histological and molecular features of solitary fibrous tumor of the extremities: Clinical correlation. Virchows Arch. 476:445–454. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ogura K, Hosoda F, Arai Y, Nakamura H, Hama N, Totoki Y, Yoshida A, Nagai M, Kato M, Arakawa E, et al: Integrated genetic and epigenetic analysis of myxofibrosarcoma. Nat Commun. 9:27652018. View Article : Google Scholar : PubMed/NCBI | |
|
Rogozhin DV, Bulycheva IV, Konovalov DM, Talalaev AG, Roshchin VY, Ektova AP, Bogoroditsky YS, Strykov VA, Kazakova AN, Olshanskaya YV, et al: Classical osteosarcoma in children and adolescent. Arkh Patol. 77:68–74. 2015.(In Russian). View Article : Google Scholar : PubMed/NCBI | |
|
Mans DR, Budhu Lall AE, Macnack VL, van Tholl JA, Zandveld EB and Vrede MA: Incidence, and gender, age and ethnic distribution of sarcomas in the republic of Suriname from 1980 to 2008. West Indian Med J. 63:121–127. 2014.PubMed/NCBI | |
|
Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, et al: The genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy. Clin Cancer Res. 25:5961–5971. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J, et al: Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9:342017. View Article : Google Scholar : PubMed/NCBI | |
|
Cote GM, He J and Choy E: Next-generation sequencing for patients with sarcoma: A single center experience. Oncologist. 23:234–242. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, Ellison D, Shurtleff S, Wu G, Wei L, et al: Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7:104–112. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Trabucco SE, Ali SM, Sokol E, Schrock AB, Albacker LA, Chung J, Xavier MF, Disel U, Miller VA, Ross JS, et al: Frequency of genomic biomarkers of response to immunotherapy in sarcoma. J Clin Oncol. 36:11579. 2018. View Article : Google Scholar | |
|
Lange AM and Lo HW: Inhibiting TRK proteins in clinical cancer therapy. Cancers (Basel). 10:1052018. View Article : Google Scholar | |
|
Wong V, Pavlick D, Brennan T, Yelensky R, Crawford J, Ross JS, Miller VA, Malicki D, Stephens PJ, Ali SM and Ahn H: Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals an LMNA-NTRK1 gene fusion responsive to Crizotinib. J Natl Cancer Inst. 108:djv3072016. View Article : Google Scholar : PubMed/NCBI | |
|
Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC and Pappo A: Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatric Blood Cancer. 63:1468–1470. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bender J, Anderson B, Bloom DA, Rabah R, McDougall R, Vats P and Mody R: Refractory and metastatic infantile fibrosarcoma harboring LMNA-NTRK1 fusion shows complete and durable response to crizotinib. Cold Spring Harb Mol Case Stud. 5:a0033762019. View Article : Google Scholar : PubMed/NCBI |
